Pazopanib
Also known as Votrient (us), Pazonat (india)
Pazopanib is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the cells of the kidneys) in adults. Pazopanib is in a class of medications called kinase inhibitors.
SMILES: CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Based on 30 units per month. US $86.61 vs India $2.94 per unit.
The savings here are large enough that a trip may still come out ahead. Adjust the numbers to your own situation — every value is an editable estimate.
- Medicine savings over 6 months
- $15,060
- Estimated travel cost
- − $2,300
- Net savings after travel
- $12,760
Even after travel, you could come out ahead by about $12,760.
Assumptions: medicine savings = (US − India monthly price) × months. Travel cost = flights + hotel × nights + buffer. Excludes consultation fees, visas, and other costs. For information only — not medical, legal, or travel advice.
Pazopanib is filled about 7.4K times a year under Medicare Part D. At the prices above, that works out to roughly:
Rough estimate. Based on Medicare Part D prescription volume (not the entire US market) scaled by the representative monthly price — actual totals depend on dose, duration and coverage.